Browse by Section 100 Item List
HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)
For Highly Specialised Drugs prescribed through public hospitals, claiming and approval of authority prescriptions is administered by Department of Human Services. Maximum quantities and repeats for Highly Specialised Drugs are listed in the Schedule. Highly Specialised Drugs prescribed through public hospitals, except Complex Authority Required Highly Specialised Drugs, are Authority required (STREAMLINED) PBS Prescriptions. Authority approvals are required for prescriptions where the dose is above the determined maximum quantity and/or number of repeats. Complex Authority Required Highly Specialised Drugs require written authority applications. Approval of authority prescriptions by Department of Human Services may be obtained either by posting an Authority Prescription Form to Department of Human Services, or by using Department of Human Services' Authority Freecall service (1800 888 333). Prescribers must quote the provider number of the hospital when applying.
Public hospital prescriptions for Highly Specialised Drugs can be dispensed by public hospital pharmacies. A patient will be required to pay a contribution for each supply of a highly specialised drug at a similar rate to the Pharmaceutical Benefits Scheme. Commonwealth subsidy is not available for hospital in-patients.
Reciprocal Health Care Agreement – Where a patient is entitled to be treated as an eligible person as a visitor from a country with which Australia has entered into a Reciprocal Health Care Agreement, the supply will be limited to the original prescription only. Repeat prescriptions for these patients are not permitted.
- MPMedical Practitioner
|Prescriber code||Item code||Name, manner of administration and form & strength||Max qty
|MP||9511N||OCTREOTIDEoctreotide 10 mg injection: modified release [1 x 10 mg vial] (&) inert substance diluent [1 x 2.5 mL syringe], 1 pack||2||2||5|
|MP||9509L||OCTREOTIDEoctreotide 100 microgram/mL injection, 5 x 1 mL ampoules||18||90||11|
|MP||9512P||OCTREOTIDEoctreotide 20 mg injection: modified release [1 x 20 mg vial] (&) inert substance diluent [1 x 2.5 mL syringe], 1 pack||2||2||5|
|MP||9513Q||OCTREOTIDEoctreotide 30 mg injection: modified release [1 x 30 mg vial] (&) inert substance diluent [1 x 2.5 mL syringe], 1 pack||2||2||5|
|MP||9508K||OCTREOTIDEoctreotide 50 microgram/mL injection, 5 x 1 mL ampoules||18||90||11|
|MP||9510M||OCTREOTIDEoctreotide 500 microgram/mL injection, 5 x 1 mL ampoules||18||90||11|
|MP||9745X||OMALIZUMABomalizumab 150 mg injection [1 x 150 mg vial] (&) inert substance diluent [1 x 1.2 mL ampoule], 1 pack||1||1||0|
|MP||10109C||OMALIZUMABomalizumab 150 mg/mL injection, 1 x 1 mL syringe||1||1||0|
|MP||10118M||OMALIZUMABomalizumab 75 mg/0.5 mL injection, 1 x 0.5 mL syringe||1||1||0|